These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 30016989)

  • 1. Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (RETNET): study protocol for a randomized controlled trial.
    Chen JX; Wileyto EP; Soulen MC
    Trials; 2018 Jul; 19(1):390. PubMed ID: 30016989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma.
    Niessen C; Unterpaintner E; Goessmann H; Schlitt HJ; Mueller-Schilling M; Wohlgemuth WA; Stroszczynski C; Wiggermann P
    J Vasc Interv Radiol; 2014 Feb; 25(2):240-7. PubMed ID: 24291001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma.
    Prajapati HJ; Dhanasekaran R; El-Rayes BF; Kauh JS; Maithel SK; Chen Z; Kim HS
    J Vasc Interv Radiol; 2013 Mar; 24(3):307-15. PubMed ID: 23375519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Embolotherapy for Neuroendocrine Tumor Liver Metastases: Prognostic Factors for Hepatic Progression-Free Survival and Overall Survival.
    Chen JX; Rose S; White SB; El-Haddad G; Fidelman N; Yarmohammadi H; Hwang W; Sze DY; Kothary N; Stashek K; Wileyto EP; Salem R; Metz DC; Soulen MC
    Cardiovasc Intervent Radiol; 2017 Jan; 40(1):69-80. PubMed ID: 27738818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver.
    Ruutiainen AT; Soulen MC; Tuite CM; Clark TW; Mondschein JI; Stavropoulos SW; Trerotola SO
    J Vasc Interv Radiol; 2007 Jul; 18(7):847-55. PubMed ID: 17609443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus after hepatic arterial embolisation therapy of metastases from gastrointestinal neuroendocrine tumours: The FFCD 1104-EVACEL-GTE phase II study.
    Walter T; Lepage C; Coriat R; Barbier E; Cadiot G; Caroli-Bosc FX; Aparicio T; Bouhier-Leporrier K; Hentic-Dhome O; Gay F; Dupont-Gossart AC; Duluc M; Lepere C; Lecomte T; Smith D; Petorin C; Di-Fiore F; Ghiringhelli F; Legoux JL; Guimbaud R; Baudin E; Lombard-Bohas C; de Baère T;
    Eur J Cancer; 2019 Dec; 123():92-100. PubMed ID: 31678771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone.
    Brown KT; Do RK; Gonen M; Covey AM; Getrajdman GI; Sofocleous CT; Jarnagin WR; D'Angelica MI; Allen PJ; Erinjeri JP; Brody LA; O'Neill GP; Johnson KN; Garcia AR; Beattie C; Zhao B; Solomon SB; Schwartz LH; DeMatteo R; Abou-Alfa GK
    J Clin Oncol; 2016 Jun; 34(17):2046-53. PubMed ID: 26834067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conventional versus Drug-Eluting Bead Transarterial Chemoembolization for Neuroendocrine Tumor Liver Metastases.
    Makary MS; Kapke J; Yildiz V; Pan X; Dowell JD
    J Vasc Interv Radiol; 2016 Sep; 27(9):1298-1304. PubMed ID: 27499157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective study of transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: an Asian cooperative study between Japan and Korea.
    Ikeda M; Arai Y; Park SJ; Takeuchi Y; Anai H; Kim JK; Inaba Y; Aramaki T; Kwon SH; Yamamoto S; Okusaka T; ;
    J Vasc Interv Radiol; 2013 Apr; 24(4):490-500. PubMed ID: 23466316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Korean Multicenter Registry of Transcatheter Arterial Chemoembolization with Drug-Eluting Embolic Agents for Nodular Hepatocellular Carcinomas: Six-Month Outcome Analysis.
    Lee M; Chung JW; Lee KH; Won JY; Chun HJ; Lee HC; Kim JH; Lee IJ; Hur S; Kim HC; Kim YJ; Kim GM; Joo SM; Oh JS
    J Vasc Interv Radiol; 2017 Apr; 28(4):502-512. PubMed ID: 27856136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal outcomes for liver-dominant metastatic breast cancer with transarterial chemoembolization with drug-eluting beads loaded with doxorubicin.
    Martin RC; Robbins K; Fagés JF; Romero FD; Rustein L; Tomalty D; Monaco R
    Breast Cancer Res Treat; 2012 Apr; 132(2):753-63. PubMed ID: 22200868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic arterial chemoembolization using drug-eluting beads in gastrointestinal neuroendocrine tumor metastatic to the liver.
    Gaur SK; Friese JL; Sadow CA; Ayyagari R; Binkert CA; Schenker MP; Kulke M; Baum R
    Cardiovasc Intervent Radiol; 2011 Jun; 34(3):566-72. PubMed ID: 21431978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment options for unresectable neuroendocrine liver metastases.
    John BJ; Davidson BR
    Expert Rev Gastroenterol Hepatol; 2012 Jun; 6(3):357-69. PubMed ID: 22646257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interventional Liver-Directed Therapy for Neuroendocrine Metastases: Current Status and Future Directions.
    D'Souza D; Golzarian J; Young S
    Curr Treat Options Oncol; 2020 May; 21(6):52. PubMed ID: 32447461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference.
    Kennedy A; Bester L; Salem R; Sharma RA; Parks RW; Ruszniewski P;
    HPB (Oxford); 2015 Jan; 17(1):29-37. PubMed ID: 25186181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoembolization of Neuroendocrine Liver Metastases Using Streptozocin and Tris-acryl Microspheres: Embozar (EMBOsphere + ZAnosaR) Study.
    Pelage JP; Fohlen A; Mitry E; Lagrange C; Beauchet A; Rougier P
    Cardiovasc Intervent Radiol; 2017 Mar; 40(3):394-400. PubMed ID: 28035432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal measurement modality and method for evaluation of responses to transarterial chemoembolization of hepatocellular carcinoma based on enhancement criteria.
    Shim JH; Han S; Shin YM; Yu E; Park W; Kim KM; Lim YS; Lee HC
    J Vasc Interv Radiol; 2013 Mar; 24(3):316-25. PubMed ID: 23312990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up.
    Dekervel J; van Malenstein H; Vandecaveye V; Nevens F; van Pelt J; Heye S; Laleman W; Van Steenbergen W; Vaninbroukx J; Verslype C; Maleux G
    J Vasc Interv Radiol; 2014 Feb; 25(2):248-55.e1. PubMed ID: 24295569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic artery embolotherapy of hepatic metastases from carcinoid tumors: value of using a mixture of cyanoacrylate and ethiodized oil.
    Winkelbauer FW; Niederle B; Pietschmann F; Thurnher S; Wildling R; Prokesch R; Lammer J
    AJR Am J Roentgenol; 1995 Aug; 165(2):323-7. PubMed ID: 7542430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial).
    Ebbers SC; Braat AJAT; Moelker A; Stokkel MPM; Lam MGEH; Barentsz MW
    Trials; 2020 Feb; 21(1):141. PubMed ID: 32024533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.